RAC media coverage, page-2223

We will be collecting cardio data in the Phase 1a stage, the issue is the small size of each dose cohort makes it hard to know if we will see anything that is of significant. Of course if we do we will report it, but I am not expecting that we will be able to say much about cardioprotection until we get to the Phase 1b stage. This limitation does not apply to the m6A analysis.

One interesting thing that has come up in conversation with a shareholder is they thought that we spend until 2026 recruiting patients and then start the trial. The way oncology trials works is the patients are recruited and treated within weeks of recruitment, not recruited and we hold off treatment until all patients are recruited. This means we will be getting data all through 2025 on the patients and how they respond to treatment.